NCT Number |
Title |
Conditions |
Interventions |
Sponsor/
Collaborators |
Phases |
NCT03346434 |
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients 6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL) |
Dermatitis, Atopic |
Drug: Dupilumab
Drug: Matching placebo |
Regeneron Pharmaceuticals
Sanofi |
Phase 2
Phase 3 |
NCT03346499 |
Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2 |
HIV |
Biological: NK cells and IL-2 |
University of Minnesota - Clinical and Translational Science Institute |
Phase 2 |
NCT03345914 |
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants 6 to <12 Years With Severe Atopic Dermatitis (AD) |
Dermatitis, Atopic |
Drug: Dupilumab
Drug: Matching Placebo
Other: Background Treatment:
Topical Corticosteroids
Other: Background Treatment: Moisturizers |
Regeneron Pharmaceuticals
Sanofi |
Phase 3 |
NCT03345043 |
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects |
Influenza |
Biological: VAL-339851
Other: Placebo |
Moderna Therapeutics |
Phase 1 |
NCT03342937 |
KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer |
Gastric Cancer|Esophagus Cancer |
Drug: Oxaliplatin
+Capecitabine
+Pembrolizumab |
Duke University|Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03342911 |
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery |
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma... |
Drug: Paclitaxel
Drug: Carboplatin
Biological: Nivolumab |
Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University |
Phase 2 |
NCT03342638 |
Maximizing Outcome of Multiple Sclerosis Transplantation |
Multiple Sclerosis, Relapsing-Remitting |
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: G-CSF
Biological: IVIg
Biological: Autologous Stem Cells |
Northwestern University |
Phase 3 |
NCT03342352 |
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) |
Squamous Cell Carcinoma of the Head and Neck |
Drug: Nivolumab
Drug: Epacadostat
Drug: Placebo
Drug: Carboplatin
Drug: Cisplatin
Drug: Cetuximab
Drug: 5-Fluorouracil |
Incyte Corporation|Bristol-Myers Squibb |
Phase 3 |
NCT03341936 |
Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck |
Squamous Cell Carcinoma of the Head and Neck |
Drug: Nivolumab
Drug: Lirilumab |
Dana-Farber Cancer Institute|Bristol-Myers Squibb |
Phase 2 |
NCT03341806 |
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma |
Glioblastoma|GBM |
Drug: Avelumab
Combination Product:
MRI-guided LITT therapy |
Icahn School of Medicine at Mount Sinai |
Phase 1 |
NCT03340883 |
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) |
Multiple Myeloma |
Biological: BION-1301 |
Aduro Biotech, Inc. |
Phase 1
Phase 2 |
NCT03347838 |
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers |
Bronchial Dysplasia|Tobacco Smoking|History of Non-Small Cell Lung Cancer|History of Head and Neck Cancer |
Drug: Nivolumab |
University of Colorado, Denver|Bristol-Myers Squibb |
Phase 2 |
NCT03341754 |
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults |
Malaria |
Biological: D/ChAd63-CA
Biological: D/ChAd63-CAT
Other: Infectivity Control (IC) Group |
U.S. Army Medical Research and Materiel Command|University of Oxford|Walter Reed Army Institute of Research (WRAIR)|United States Agency for International Development (USAID) |
Phase 1 |
NCT03347708 |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
Degenerative Disc Disease |
Biological: IDCT
Drug: Saline Solution
Drug: Sodium Hyaluronate |
DiscGenics, Inc. |
Phase 1
Phase 2 |
NCT03346135 |
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma |
Plasma Cell Myeloma|Secondary Amyloidosis |
Procedure: Autologous
Hematopoietic Stem
Cell Transplantation
Drug: Melphalan
Biological: Daratumumab
Other: Laboratory
Biomarker Analysis |
City of Hope Medical Center |
Phase 2 |
NCT03345082 |
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD |
Neovascular Age-related Macular Degeneration |
Biological: OPT-302|Biological: ranibizumab|Other: sham intravitreal injection |
Opthea Limited |
Phase 2 |
NCT03343626 |
Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants |
Virus, Zika|Zika Virus Disease|Flavivirus Infections|Healthy Participants |
Drug: Placebo|Biological: PIZV |
Takeda |
Phase 1 |
NCT03347279 |
Phase 3 Study to Evaluate the Efficacy & Safety of Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma. |
Asthma |
Biological: Experimental: Tezepelumab|Other: Placebo |
AstraZeneca|Amgen |
Phase 3 |
NCT03347188 |
A Study Comparing 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of PPTH |
Post-Traumatic Headache |
Drug: Fremanezumab|Drug: Placebo |
Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries |
Phase 2 |